Ascendis Pharma A/S (ASND) EPS Estimated At $-0.90

March 22, 2018 - By Michael Collier

 Ascendis Pharma A/S (ASND) EPS Estimated At $ 0.90

Analysts expect Ascendis Pharma A/S (NASDAQ:ASND) to report $-0.90 EPS on March, 28.They anticipate $0.35 EPS change or 63.64 % from last quarter’s $-0.55 EPS. After having $-1.22 EPS previously, Ascendis Pharma A/S’s analysts see -26.23 % EPS growth. The stock increased 3.03% or $1.94 during the last trading session, reaching $66.04. About 205,771 shares traded or 4.87% up from the average. Ascendis Pharma A/S (NASDAQ:ASND) has risen 96.01% since March 22, 2017 and is uptrending. It has outperformed by 79.31% the S&P500.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Coverage

Among 7 analysts covering Ascendis Pharma (NASDAQ:ASND), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Ascendis Pharma has $78 highest and $28.0 lowest target. $54.29’s average target is -17.79% below currents $66.04 stock price. Ascendis Pharma had 21 analyst reports since September 26, 2016 according to SRatingsIntel. Bank of America maintained Ascendis Pharma A/S (NASDAQ:ASND) rating on Tuesday, September 26. Bank of America has “Buy” rating and $46.0 target. Credit Suisse maintained the stock with “Outperform” rating in Friday, September 22 report. The firm earned “Buy” rating on Friday, September 22 by Wells Fargo. The stock of Ascendis Pharma A/S (NASDAQ:ASND) earned “Outperform” rating by Wedbush on Monday, September 26. On Friday, January 5 the stock rating was maintained by Wedbush with “Buy”. The firm has “Buy” rating by Wedbush given on Friday, September 22. The company was maintained on Thursday, January 25 by Bank of America. J.P. Morgan maintained it with “Buy” rating and $60.0 target in Wednesday, January 17 report. The firm has “Buy” rating given on Monday, September 11 by Wedbush. The rating was maintained by Wedbush on Tuesday, February 6 with “Buy”.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. The company has market cap of $2.74 billion. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. It currently has negative earnings. The firm is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

More notable recent Ascendis Pharma A/S (NASDAQ:ASND) news were published by: which released: “Ascendis Pharma A/S Announces Year-End 2017 Financial Results and Business …” on March 16, 2018, also with their article: “Ascendis Pharma shares surge 42% on competitor’s flop” published on September 22, 2017, published: “5 Biggest Price Target Changes For Tuesday” on March 20, 2018. More interesting news about Ascendis Pharma A/S (NASDAQ:ASND) were released by: and their article: “Ascendis Pharma Announces Two Posters on Rare Disease Pipeline Programs at …” published on March 19, 2018 as well as‘s news article titled: “Ascendis Pharma A/S Reports First Quarter 2017 Financial Results” with publication date: May 23, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.